Navegando por Palavras-chave "myopia"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group
    (Bmj Publishing Group, 2018) Chhablani, Jay; Paulose, Remya Mareen; Lasave, Andres F.; Wu, Lihteh; Carpentier, Cristian; Maia, Mauricio [UNIFESP]; Lujan, Silvio; Rojas, Sergio; Serrano, Martin; Berrocal, Maria H.; Arevalo, J. Fernando
    Purpose To report the long-term anatomical and visual outcomes of intravitreal bevacizumab (IVB) monotherapy in naive choroidal neovascularisation (CNV) caused by myopia. Methods Retrospective analysis of naive CNV secondary to myopia that underwent antivascular endothelial growth factor monotherapy was performed. Collected data included demographic details, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were resolution of CNV activity at the last visit. Secondary outcomes included change in visual acuity, number of injections and adverse events. Results Thirty-three eyes of 31 subjects with a mean age of 51.4816.4 years were included. The mean follow-up was 66.47 months. 27 eyes had type 2 CNV and the rest seven eyes had type 1 CNV. The mean number of IVB injections per eye was 4.9. Mean visual acuity at baseline reduced from 0.65 +/- 0.33logMAR units (Snellen equivalent=20/89) to 0.73 +/- 0.50logMAR units (20/107) at final follow-up (p=0.003). The mean central macular thickness decreased from 309.31 +/- 86 mu m at baseline to 267.5 +/- 70.89 mu m at the last visit (p=0.03). However, visual acuity was maintained (+/- 1line of baseline) in 13 eyes (39.4%), 2line improvement in nine (27.3%) eyes and more than two lines worsening in 11 eyes (33.3%). Foveal atrophy was observed at baseline and last visit in 6 (12.5%) and 14 (29.1%), respectively (p=0.007). No systemic adverse events were observed. Conclusion IVB monotherapy is safe and effective for long-term treatment of CNV secondary to myopia in real life.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Photorefractive Keratectomy With Mitomycin C After Penetrating and Lamellar Keratoplasty
    (Lippincott Williams & Wilkins, 2010-10-01) Forseto, Adriana dos Santos; Marques, Junia Cabral; Nose, Walton [UNIFESP]; Eye Clin Day Hosp; Universidade Federal de São Paulo (UNIFESP)
    Purpose: To assess the safety and efficacy of photorefractive keratectomy with mitomycin C (PRK-MMC) to correct refractive errors after corneal transplantation.Methods: This was a prospective and noncomparative study of 36 eyes that underwent PRK-MMC after penetrating (n = 34) or lamellar (n = 2) keratoplasty. After mechanical epithelial removal and photoablation, a sponge with mitomycin C 0.02% was applied to the stromal bed for 1 minute. the uncorrected and best-corrected visual acuities, refraction, and complications were assessed.Results: the average follow-up was 16.27 +/- 8.38 months (range, 6-30.5 months). the spherical equivalent decreased from -3.95 +/- 4.11 to -1.07 +/- 1.45 diopters (D) postoperatively (P < 0.001). the mean preoperative astigmatism was 4.42 +/- 1.69 D (range, 1.00-7.25 D); however, surgical correction was limited to 6.00 D. Vector analysis of astigmatic correction showed an index of success of 55%. At the last follow-up, 41.7% (n = 15) and 61.1% (n = 22) of the eyes were within +/- 0.50 and +/- 1.00 D of emmetropia, respectively. Nineteen eyes (52.8%) achieved an uncorrected visual acuity of 20/40 or better. the best-corrected visual acuity remained within 1 line of the preoperative values in 26 cases (72.2%), improved in 8 (22.2%), and decreased in 2 (5.6%). Endothelial cell decompensation was observed in 1 eye (2.8%) 11 months postoperatively, and haze developed in 3 cases (8.3%).Conclusions: PRK-MMC may be an option to correct refractive errors after keratoplasty. A low preoperative endothelial cell count and haze may affect the safety outcomes.